NewsBytes
    Hindi Tamil Telugu
    More
    In the news
    Narendra Modi
    Amit Shah
    Box Office Collection
    Bharatiya Janata Party (BJP)
    OTT releases
    Hindi Tamil Telugu
    NewsBytes
    User Placeholder

    Hi,

    Logout


    India Business World Politics Sports Technology Entertainment Auto Lifestyle Inspirational Career Bengaluru Delhi Mumbai Visual Stories Find Cricket Statistics Phones Reviews Fitness Bands Reviews Speakers Reviews

    Download Android App

    Follow us on
    • Facebook
    • Twitter
    • Linkedin
     
    Home / News / Technology News / Moderna COVID-19 vaccine produces lasting immune response: Study
    Moderna COVID-19 vaccine produces lasting immune response: Study
    1/7
    Technology 3 min read

    Moderna COVID-19 vaccine produces lasting immune response: Study

    By Sneha Das
    (PTI desk)
    Sep 15, 2021
    05:29 pm
    Moderna COVID-19 vaccine produces lasting immune response: Study
    The Moderna COVID-19 vaccine led to strong immune and antibody responses for at least six months

    Immunity generated by the Moderna COVID-19 vaccine lasts for at least six months, and there is no indicator that vaccinated people will need a booster shot, according to a study. The research, published in the journal Science, noted that this time point of six months is critical because that is when true immune memory has formed.

    2/7

    The strong immune memory lasted in all age groups

    While the Moderna COVID-19 vaccine led to strong immune and antibody responses for at least six months after clinical trial participants were fully vaccinated, it is likely that the immune response could last much longer, researchers said. They also show that this strong immune memory lasted in all age groups tested, including in people over age 70, a demographic especially vulnerable to severe COVID-19.

    3/7

    Researchers compared recovered COVID-19 patients to vaccine trial participants

    "The immune memory was stable, and that was impressive. That's a good indicator of the durability of mRNA vaccines," said Shane Crotty, a professor at La Jolla Institute for Immunology (LJI) in the US. The researchers compared recovered COVID-19 patients to vaccine trial participants who received a 25-microgram dose of the Moderna vaccine during the phase 1 clinical trials.

    4/7

    Participants received two 25-microgram injections of vaccine 28 days apart

    "We wanted to see if a quarter of the dose is able to induce any immune response," said the study's first author Jose Mateus Trivino, a postdoctoral fellow at LJI. "We had the opportunity to receive the samples from the original Moderna phase 1 trial participants who had received two 25-microgram injections of the vaccine, 28 days apart," Trivino said.

    5/7

    T cell, antibody response in smaller dose group still strong

    While researchers don't know whether this smaller dose is as effective as the standard dose, the study shows that the T cell and antibody response in the smaller dose group is still strong.

    6/7

    Moderna vaccine spurs adaptive immune response to SARS-CoV-2 spike protein

    They found that the Moderna vaccine spurs an adaptive immune response to the SARS-CoV-2 spike protein nearly identical to the immune system's response to a natural infection. The coronavirus uses the spike protein to enter and infect the cells. "The response is comparable. It's not higher and it's not lower," said LJI Research Assistant Professor Daniela Weiskopf.

    7/7

    Study shows power of 'cross-reactive' T cells

    The study also shows the power of "cross-reactive" T cells, immune cells which trigger a faster and better antibody response. The researchers found that people with cross-reactive T cells had significantly stronger antibody responses to both doses of the vaccine.

    Facebook
    Whatsapp
    Twitter
    Linkedin
    Related News
    Research
    COVID-19 Vaccine
    Moderna Inc

    Research

    No serious vaccine side effects in breastfeeding moms, infants: Study Pfizer
    Indian-led team develops online search system to limit COVID-19 misinformation Canada
    Single COVAXIN dose might be enough for those previously infected Indian Council of Medical Research (ICMR)
    COVID-19 most-transmissible two days before, three days after symptoms appear SARS-CoV-2

    COVID-19 Vaccine

    35 lakh doses of J&J COVID-19 vaccine reach Kasauli lab Johnson & Johnson
    England school children aged 12-15yrs to be offered COVID-19 vaccine Pfizer
    WHO nod for COVAXIN expected by September-end: Report World Health Organization
    COVID-19 vaccines for younger kids could be available from October Pfizer

    Moderna Inc

    Japan suspends 1.63mn Moderna vaccine doses after contamination found Japan
    No sign of Pfizer, Moderna vaccines in breast milk: Study Pfizer
    India offered 7.5mn doses of Moderna vaccine under COVAX program Drugs Controller General of India
    Moderna vaccine arriving in India in 2-3 days: Report Vaccine
    Next News Article

    Love Technology News?

    Subscribe to stay updated.

    Science Thumbnail
    Indian Premier League (IPL) Celebrity Hollywood Bollywood UEFA Champions League Tennis Football Smartphones Cryptocurrency Upcoming Movies Premier League Cricket News Latest automobiles Latest Cars Upcoming Cars Latest Bikes Upcoming Tablets
    About Us Privacy Policy Terms & Conditions Contact Us Ethical Conduct Grievance Redressal News News Archive Topics Archive Download DevBytes Find Cricket Statistics
    Follow us on
    Facebook Twitter Linkedin
    All rights reserved © NewsBytes 2023